Login to Your Account



Earnings Roundup


Wednesday, May 4, 2011
Dendreon Corp., of Seattle, reported $28.1 million in revenue for the first quarter, thanks to sales of prostate cancer vaccine Provenge (sipuleucel-T). The figure was just barely shy of analyst expectations of $28.9 million. Dendreon also reported $15 million in April Provenge sales, which analysts viewed as encouraging.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription